Detalles de la búsqueda
1.
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency.
Pituitary;
26(1): 57-72, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36380045
2.
The biochemical diagnosis of adrenal insufficiency with modern cortisol assays: Reappraisal in the setting of opioid exposure and hospitalization.
Clin Endocrinol (Oxf);
96(1): 21-29, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34498295
3.
Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
Pituitary;
25(6): 795-809, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36002784
4.
Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
Pituitary;
25(6): 959-970, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36219274
5.
Current concepts of the diagnosis of adult growth hormone deficiency.
Rev Endocr Metab Disord;
22(1): 109-116, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32959175
6.
Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program.
Pituitary;
24(4): 611-621, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33709288
7.
Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.
Pituitary;
24(1): 104-115, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33216275
8.
A Pituitary Society update to acromegaly management guidelines.
Pituitary;
24(1): 1-13, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33079318
9.
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Clin Endocrinol (Oxf);
91(6): 776-785, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31465533
10.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
Endocr Pract;
25(11): 1191-1232, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31760824
11.
Characterization of cyclic Cushing's disease using late night salivary cortisol testing.
Clin Endocrinol (Oxf);
89(3): 336-345, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29873834
12.
Is GH dosing optimal in female patients with adult-onset GH deficiency? An analysis from the NordiNet® International Outcome Study.
Clin Endocrinol (Oxf);
86(6): 798-805, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28306165
13.
The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet® International Outcome Study.
Clin Endocrinol (Oxf);
86(2): 192-198, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27736009
14.
Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Pituitary;
20(1): 129-135, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27631335
15.
Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians.
Pituitary;
20(4): 422-429, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28275992
16.
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Endocr Pract;
23(8): 962-970, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28614003
17.
Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study.
Pituitary;
19(3): 332-41, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26897383
18.
Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.
Pituitary;
24(1): 116, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33313999
19.
Osilodrostat, a potent oral 11ß-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
Pituitary;
19(2): 138-48, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26542280
20.
PATIENTS' PERCEPTION ON CLINICAL OUTCOME AND QUALITY OF LIFE AFTER A DIAGNOSIS OF CUSHING SYNDROME.
Endocr Pract;
22(1): 51-67, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26437213